The looming deadline for the paraquat decision has sparked a heated debate among Parkinson's disease experts and the Australian Pesticides and Veterinary Medicines Authority (APVMA). As the regulator prepares to make a final call, top neurologists in Australia are expressing deep concerns over their lack of engagement and the potential oversight of critical real-world data linking paraquat to Parkinson's disease.
The APVMA's proposed regulatory decision, released in 2024, claims that the available epidemiology data is insufficient to establish a link between paraquat exposure and neurotoxicity, including Parkinson's disease, in occupational settings. This stance directly contradicts the global consensus among movement disorders specialists, who argue that exposure to paraquat significantly increases the risk of developing Parkinson's disease.
Associate Professor Wesley Thevathasan, a movement disorders specialist, highlights the APVMA's disregard for recent human studies and epidemiological evidence. He emphasizes that multiple studies have shown a threefold increase in the risk of Parkinson's disease among those exposed to paraquat, a correlation that aligns with the methodology used to prove the link between smoking and lung cancer.
Thevathasan's concerns are shared by over 70 medical experts and clinicians, who have submitted evidence linking paraquat to Parkinson's disease. Neurologist Dr. Kelly Bertram, president of the Movement Disorder Society of Australia and New Zealand, warns that the APVMA's approach is concerning, as it fails to consider the precautionary principle, which is applied to other significant exposures like medications.
The international context adds fuel to the fire. The US Environmental Protection Agency (EPA) has recently increased uncertainty about paraquat's volatility, potentially impacting workers and bystanders. This development has prompted Vermont to become the first US state to ban paraquat, a significant shift from federal policy.
At the heart of the dispute is the weight given to epidemiology, which examines disease patterns in human populations. While laboratory experiments are not possible with paraquat, real-world exposure data can be compelling, as demonstrated by the studies showing a threefold risk increase among exposed individuals.
As the APVMA reviews its assessments of paraquat's volatility, the regulator faces a challenging decision. The agriculture industry relies on paraquat for weed control, and farm groups argue that it is essential for managing resistant weeds. However, the potential health risks and the growing body of evidence linking paraquat to Parkinson's disease cannot be ignored.
In conclusion, the paraquat decision is a complex issue that requires a careful balance between agricultural needs and public health. The APVMA's engagement with Parkinson's disease experts and the consideration of real-world data will be crucial in determining the future of this controversial weed killer.
